Assessment of bleeding in chronic liver disease and coagulopathy using the IMPROVE bleeding criteria

Background: In this study, the authors utilized the IMPROVE (International Medical Prevention Registry on Venous Thromboembolism) bleeding definition to explore the safety profile of pharmacologic venous thromboembolism (VTE) prophylaxis in patients with chronic liver disease (CLD) and concurrent co...

Full description

Saved in:
Bibliographic Details
Main Author: Chamoun, Nibal (author)
Other Authors: Ramia, Elsy (author), Lteif, Christelle (author), Salameh, Pascale (author), Zantout, Hala (author), Ghanem, Georges (author), Chatila, Rajaa (author)
Format: article
Published: 2019
Online Access:http://hdl.handle.net/10725/10710
https://doi.org/10.1080/03007995.2018.1525343
http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php
https://www.tandfonline.com/doi/full/10.1080/03007995.2018.1525343
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1864513487123775488
author Chamoun, Nibal
author2 Ramia, Elsy
Lteif, Christelle
Salameh, Pascale
Zantout, Hala
Ghanem, Georges
Chatila, Rajaa
author2_role author
author
author
author
author
author
author_facet Chamoun, Nibal
Ramia, Elsy
Lteif, Christelle
Salameh, Pascale
Zantout, Hala
Ghanem, Georges
Chatila, Rajaa
author_role author
dc.creator.none.fl_str_mv Chamoun, Nibal
Ramia, Elsy
Lteif, Christelle
Salameh, Pascale
Zantout, Hala
Ghanem, Georges
Chatila, Rajaa
dc.date.none.fl_str_mv 2019-05-31T10:20:49Z
2019-05-31T10:20:49Z
2019
2019-05-31
dc.identifier.none.fl_str_mv 1473-4877
http://hdl.handle.net/10725/10710
https://doi.org/10.1080/03007995.2018.1525343
Chamoun, N., Ramia, E., Lteif, C., Salameh, P., Zantout, H., Ghanem, G., & Chatila, R. (2019). Assessment of bleeding in chronic liver disease and coagulopathy using the IMPROVE bleeding criteria. Current Medical Research and Opinion, 35(3), 427-433.
http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php
https://www.tandfonline.com/doi/full/10.1080/03007995.2018.1525343
dc.language.none.fl_str_mv en
dc.relation.none.fl_str_mv Current Medical Research and Opinion
dc.rights.*.fl_str_mv info:eu-repo/semantics/openAccess
dc.title.none.fl_str_mv Assessment of bleeding in chronic liver disease and coagulopathy using the IMPROVE bleeding criteria
dc.type.none.fl_str_mv Article
info:eu-repo/semantics/publishedVersion
info:eu-repo/semantics/article
description Background: In this study, the authors utilized the IMPROVE (International Medical Prevention Registry on Venous Thromboembolism) bleeding definition to explore the safety profile of pharmacologic venous thromboembolism (VTE) prophylaxis in patients with chronic liver disease (CLD) and concurrent coagulopathy (INR ≥1.5). Methods: A retrospective study was conducted on 193 adult patient admissions with a diagnosis of CLD and INR ≥1.5 not due to therapeutic anticoagulation. Patients were stratified based on their receipt of pharmacological thromboprophylaxis or not during hospitalization. The rates of overall bleeding, defined as the composite of major bleeding and clinically relevant non-major bleeding; major bleeding; and clinically relevant non-major bleeding, within 14 days of admission were evaluated. Secondary endpoints included the rates of thrombosis and mortality. Results: The composite of overall bleeding occurred in 17.6% of the admissions. More patients in the group not receiving pharmacological thromboprophylaxis had overall bleeding (18.5% vs 10%), major bleeding (13.3% vs 10%), and clinically relevant non-major bleeding (14.5% vs 5%), with overlapping 95% CI. When stratified per pharmacological thromboprophylaxis status, IMPROVE bleeding risk score (BRS) ≥ 7 was associated with higher rates of overall bleeding, major bleeding, and clinically relevant non-major bleeding as compared to IMPROVE BRS <7, whether patients received or did not receive pharmacological thromboprophylaxis. The overall incidence of in-hospital mortality among our study population was 15.5%. Receiving pharmacological thromboprophylaxis was markedly associated with higher in-hospital mortality (OR = 16.58, 95% CI = 4.47–61.45). Conclusion: This study shows that the IMPROVE BRS calculated on admission may serve as a guide for omission of thromboprophylaxis in advanced CLD.
eu_rights_str_mv openAccess
format article
id LAURepo_deb2f4ad82c934b3ebde4fab6aebae2f
identifier_str_mv 1473-4877
Chamoun, N., Ramia, E., Lteif, C., Salameh, P., Zantout, H., Ghanem, G., & Chatila, R. (2019). Assessment of bleeding in chronic liver disease and coagulopathy using the IMPROVE bleeding criteria. Current Medical Research and Opinion, 35(3), 427-433.
language_invalid_str_mv en
network_acronym_str LAURepo
network_name_str Lebanese American University repository
oai_identifier_str oai:laur.lau.edu.lb:10725/10710
publishDate 2019
repository.mail.fl_str_mv
repository.name.fl_str_mv
repository_id_str
spelling Assessment of bleeding in chronic liver disease and coagulopathy using the IMPROVE bleeding criteriaChamoun, NibalRamia, ElsyLteif, ChristelleSalameh, PascaleZantout, HalaGhanem, GeorgesChatila, RajaaBackground: In this study, the authors utilized the IMPROVE (International Medical Prevention Registry on Venous Thromboembolism) bleeding definition to explore the safety profile of pharmacologic venous thromboembolism (VTE) prophylaxis in patients with chronic liver disease (CLD) and concurrent coagulopathy (INR ≥1.5). Methods: A retrospective study was conducted on 193 adult patient admissions with a diagnosis of CLD and INR ≥1.5 not due to therapeutic anticoagulation. Patients were stratified based on their receipt of pharmacological thromboprophylaxis or not during hospitalization. The rates of overall bleeding, defined as the composite of major bleeding and clinically relevant non-major bleeding; major bleeding; and clinically relevant non-major bleeding, within 14 days of admission were evaluated. Secondary endpoints included the rates of thrombosis and mortality. Results: The composite of overall bleeding occurred in 17.6% of the admissions. More patients in the group not receiving pharmacological thromboprophylaxis had overall bleeding (18.5% vs 10%), major bleeding (13.3% vs 10%), and clinically relevant non-major bleeding (14.5% vs 5%), with overlapping 95% CI. When stratified per pharmacological thromboprophylaxis status, IMPROVE bleeding risk score (BRS) ≥ 7 was associated with higher rates of overall bleeding, major bleeding, and clinically relevant non-major bleeding as compared to IMPROVE BRS <7, whether patients received or did not receive pharmacological thromboprophylaxis. The overall incidence of in-hospital mortality among our study population was 15.5%. Receiving pharmacological thromboprophylaxis was markedly associated with higher in-hospital mortality (OR = 16.58, 95% CI = 4.47–61.45). Conclusion: This study shows that the IMPROVE BRS calculated on admission may serve as a guide for omission of thromboprophylaxis in advanced CLD.PublishedN/A2019-05-31T10:20:49Z2019-05-31T10:20:49Z20192019-05-31Articleinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article1473-4877http://hdl.handle.net/10725/10710https://doi.org/10.1080/03007995.2018.1525343Chamoun, N., Ramia, E., Lteif, C., Salameh, P., Zantout, H., Ghanem, G., & Chatila, R. (2019). Assessment of bleeding in chronic liver disease and coagulopathy using the IMPROVE bleeding criteria. Current Medical Research and Opinion, 35(3), 427-433.http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.phphttps://www.tandfonline.com/doi/full/10.1080/03007995.2018.1525343enCurrent Medical Research and Opinioninfo:eu-repo/semantics/openAccessoai:laur.lau.edu.lb:10725/107102024-05-17T13:10:14Z
spellingShingle Assessment of bleeding in chronic liver disease and coagulopathy using the IMPROVE bleeding criteria
Chamoun, Nibal
status_str publishedVersion
title Assessment of bleeding in chronic liver disease and coagulopathy using the IMPROVE bleeding criteria
title_full Assessment of bleeding in chronic liver disease and coagulopathy using the IMPROVE bleeding criteria
title_fullStr Assessment of bleeding in chronic liver disease and coagulopathy using the IMPROVE bleeding criteria
title_full_unstemmed Assessment of bleeding in chronic liver disease and coagulopathy using the IMPROVE bleeding criteria
title_short Assessment of bleeding in chronic liver disease and coagulopathy using the IMPROVE bleeding criteria
title_sort Assessment of bleeding in chronic liver disease and coagulopathy using the IMPROVE bleeding criteria
url http://hdl.handle.net/10725/10710
https://doi.org/10.1080/03007995.2018.1525343
http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php
https://www.tandfonline.com/doi/full/10.1080/03007995.2018.1525343